The North America Gene Editing Market was valued at $1420.8 Million in 2024 and projected to reach to $2064.6 Million by 2029, representing a compound annual growth rate of 7.8%. North America's gene editing market is poised for continued expansion through 2029, driven by increasing clinical adoption of CRISPR-based therapeutics and growing investment in rare genetic disease treatments.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America commands the largest share of the global gene editing market, valued at $1,420.8 million in 2024, reflecting the region's advanced technological capabilities and healthcare infrastructure superiority.
The region benefits from substantial government and private sector R&D funding, with leading biotech hubs in the US and Canada driving innovation in CRISPR, base editing, and prime editing technologies.
FDA and Health Canada provide clear pathways for gene editing therapies, accelerating clinical trials and commercialization compared to other global regions, fostering investor confidence.
North America's gene editing market is projected to reach $2,064.6 million by 2029, representing a 7.8% CAGR, demonstrating sustained demand and market maturation in therapeutic applications.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Collaborates with Beam Therapeutics to develop in vivo base editing therapies targeting rare genetic diseases affecting the liver, muscles, and central nervous system. The programs utilize precision genome editing and lipid nanoparticle-based delivery technologies. | Supports the development of targeted genetic medicines, enables precise modification of disease-associated DNA sequences, and advances research into potential treatments for inherited disorders. |
|
|
Supports genome editing research through its Somatic Cell Genome Editing (SCGE) program, focusing on CRISPR-based technologies, targeted delivery systems, genome editing efficiency, and safety evaluation for therapeutic applications. | Accelerates the development of genome editing tools, improves editing specificity and delivery efficiency, supports off-target analysis, and advances research into potential gene editing therapies for genetic diseases. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CROS & CDMOS (End User) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 10.2% from 2024 to 2029 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 4.67 (2024) |
| Revenue Forecast (Billions) | ~USD 7.59 (2029) |
| Segments Covered | Offering, Type, Technique, Technology, Application, End User |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| EPPENDORF AG | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| ILLUMINA INC | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| CALYXT | United States | Public Company | RTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects, |
| MAXCYTE, INC | United States | Public Company | ExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables, |
| BECKMAN COULTER | United States | Private Company | Clinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments, |
| TAKEDA PHARMACEUTICAL COMPANY | Japan | Public Company | Gastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables), |
| REVVITY, INC. | United States | Public Company | Diagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment), |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| LONZA | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| SANGAMO THERAPEUTICS | United States | Public Company | Hemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant), |
| PRECISION BIOSCIENCES | United States | Public Company | ARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243), |
| CELLECTIS S.A. | France | Public Company | Allogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue, |
| REGENERON PHARMACEUTICALS, INC. | United States | Public Company | EYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics), |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related), |
Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.
Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.
Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.
MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.
Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.
Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.
Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.
Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.
Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.
GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.
Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.
Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.
Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.
Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.
Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.
Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.
Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.
| Country | 2025 size (native) |
|---|---|
| US | USD 1026.7 Million |
| Canada | USD 112.6 Million |
North America's gene editing market was valued at $1,420.8 million in 2024 and is expected to grow to $2,064.6 million by 2029.
North America's gene editing market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2029.
North America's market growth is driven by advanced healthcare infrastructure, substantial R&D investments, supportive regulatory frameworks, increasing clinical applications, and rising prevalence of genetic disorders.
North America's market is dominated by CRISPR technology, with growing adoption of base editing and prime editing platforms for therapeutic development.
North America leads globally due to robust intellectual property protections, abundant venture capital funding, established regulatory pathways, and strong collaboration between academic institutions and biotechnology companies.
This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary research was used primarily to identify and gather information for this extensive, technical, market-oriented, and commercial study. The secondary sources referred to for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global gene editing market, and the findings were validated through primary research.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
The global gene editing market size was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Gene editing refers to technologies used to modify, insert, delete, or regulate specific DNA sequences in cells and organisms. These technologies enable targeted genetic modifications through approaches such as CRISPR-Cas, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), base editing, and other genome engineering techniques. The gene editing market includes products such as reagents & consumables and software & systems, as well as specialized services such as cell line development & characterization, gRNA synthesis & vector construction, and library construction & screening. These products and services are widely used in cell line engineering, genome editing, drug discovery and development, and genetic research. They also support applications in biotechnology, biopharmaceutical production, and therapeutic development. Rising investment in genetic research, advances in genome-editing technologies, and the growing adoption of precision medicine are driving demand for gene editing products and services across pharmaceutical, biotechnology, and academic research institutions.
Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
Company Information
Segment Analysis
Full forecast, segment splits, and company analysis for all Gene Editing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report